Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

• Published in: The New England journal of medicine Vol. 335; no. 26; pp. 1950 - 1955
• Main Authors: Alberts, David S, Liu, P.Y, Hannigan, Edward V, O'Toole, Robert, Williams, Stephen D, Young, James A, Franklin, Ernest W, Clarke-Pearson, Daniel L, Malviya, Vinay K, DuBeshter, Brent, Adelson, Mark D, Hoskins, William J
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 26-12-1996
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Biological and medical sciences; Cancer therapies; Carcinoma - drug therapy; Carcinoma - mortality; Carcinoma - pathology; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cyclophosphamide - administration & dosage; Female; Hearing Disorders - chemically induced; Humans; Infusions, Intravenous; Infusions, Parenteral; Leukopenia - chemically induced; Medical sciences; Medical treatment; Middle Aged; Neoplasm Staging; Oncology; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Pharmacology. Drug treatments; Survival Analysis; Antineoplastic agent; Human; Drug combination; Intraperitoneal administration; Carcinoma; Intravenous administration; Treatment efficiency; Malignant tumor; Cisplatin; Female genital diseases; Ovarian diseases; Ovary; Chemotherapy; Cyclophosphamide; Female; Advanced stage; Platinum II Complexes
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199612263352603

Ovarian cancer, the leading cause of death from gynecologic cancer in the United States, is one of the few solid tumors in which the five-year survival rate for patients has improved in recent years.
1
,
2
Nevertheless, most women with advanced ovarian cancer die of the disease. Even those with stage III cancer and minimal residual intraperitoneal masses (<2 cm in the greatest dimension) have a median survival of only about 40 months.
3
,
4
Standard chemotherapy for advanced ovarian cancer includes a platinum analogue (either cisplatin or carboplatin). In an attempt to maximize its activity against ovarian cancer, cisplatin has been . . .